• Elranatamab-bcmm] reflects our ongoing commitment to developing scientific breakthroughs that meaningfully improve outcomes for people with cancer. (pharmtech.com)
  • Additionally, in the past few decades, researchers and scientists have made, and continue to make, advances in new treatments to manage multiple myeloma and improve outcomes. (bannerhealth.com)
  • Based on our findings, melphalan flufenamide is an important addition to the treatment armamentarium, with the potential to meaningfully improve outcomes in an area of important unmet medical need. (ahdbonline.com)
  • Survival of multiple myeloma has almost doubled over the last decade, and the very positive outcomes from use of the three-drug combination will likely further improve outcomes," he says. (sciencedaily.com)
  • A method combining two distinct immune system-based treatments may help to improve outcomes for patients with glioblastomas and other solid tumors. (massgeneral.org)
  • It aims to improve outcomes by ensuring the most effective investigations and treatment. (bvsalud.org)
  • Multiple myeloma: 2014 update on diagnosis, risk-stratification, and management. (scielo.br)
  • The aims of the present study were to describe clinical features at diagnosis, response to treatment and survival in 282 patients with active newly-diagnosed MM (NDMM) and compare outcomes between patients younger and older than 65 years. (scielo.br)
  • Characteristics of the disease at diagnosis, first-line treatment and response, date of progression or death and cause of mortality were detailed. (scielo.br)
  • The era of precision medicine is also ushering in new and more individualised approaches to screening, diagnosis, disease assessment and treatment decision-making. (janssen.com)
  • The International Myeloma Foundation (IMF) has begun a multiyear, multidisciplinary initiative, M-Power Charlotte, which is designed to promote the early diagnosis and treatment of myeloma in the Black community. (ascopost.com)
  • The latest research data show that African American myeloma patients do just as well, or even better than, White patients when barriers to early diagnosis and treatment are eliminated," said Joseph Mikhael, MD , Chief Medical Officer of the IMF. (ascopost.com)
  • Along with educating the Charlotte area's at-risk individuals and their health-care providers about early myeloma symptoms, the M-Power Charlotte team seeks to identify and eliminate hurdles that prevent people from receiving the appropriate diagnosis and care. (ascopost.com)
  • knowcancer.com is intended to be solely for informational purposes and should not be a substitute for professional medical advice, diagnosis or treatment. (knowcancer.com)
  • Proper diagnosis is critical to effective care as there are many subtypes of multiple myeloma. (bannerhealth.com)
  • The head and neck oncology nurse navigator (ONN) is a unique and critical position to help patients, their families, and their caregivers as they face their diagnosis and undergo treatment. (oncologynurseadvisor.com)
  • Raithel, a 64-year-old resident of Grosse Ile, received a multiple myeloma diagnosis in 2011. (karmanos.org)
  • He was a passionate outdoorsman and hiker before his diagnosis and strives to get back to that caliber of athleticism around his treatments. (karmanos.org)
  • This booklet describes some of the first steps you will want to take after receiving a myeloma diagnosis, as well as what you can expect from your treatment team. (themmrf.org)
  • It is important for individuals who are experiencing symptoms of MGRS to seek medical attention promptly in order to receive an accurate diagnosis and appropriate treatment. (articleinsider.com)
  • There has been a paradigm shift in the way we manage every aspect of the disease, from diagnosis and prognosis to treatment. (cancernetwork.com)
  • 1] Introduction of the free light chain assay as well as sensitive molecular and flow-based techniques have enabled more sensitive and specific estimates of tumor burden for both diagnosis and treatment monitoring. (cancernetwork.com)
  • 1. Rajkumar SV, Kyle RA: Multiple myeloma: Diagnosis and treatment. (cancernetwork.com)
  • Leading experts in oncology provide the most up-to-date information in these workshops to help you and your loved ones better understand and cope with your cancer diagnosis, treatment options, quality-of-life concerns, treatment side effects, pain management, doctor-patient communication and other important topics. (player.fm)
  • The most widely accepted schema for the diagnosis of multiple myeloma (MM) uses particular combinations of laboratory, imaging, and procedure findings as diagnostic criteria. (medscape.com)
  • Confirmed diagnosis of symptomatic multiple myeloma (MM). (who.int)
  • Of these, 27.91% had a main diagnosis indicating the transplantation of Multiple Myeloma (MM), and 58.14 received autologous transplantation. (bvsalud.org)
  • It was observed that the patient had psychological suffering from the diagnosis until the end. (bvsalud.org)
  • The study met the key secondary endpoint of OS, demonstrating that patients with relapsed or refractory multiple myeloma treated with KYPROLIS ® (carfilzomib) and dexamethasone (Kd) lived 7.6 months longer than those treated with Velcade ® (bortezomib) and dexamethasone (Vd) (median OS 47.6 months for Kd versus 40.0 for Vd, HR = 0.79, 95 percent CI, 0.65 - 0.96). (amgen.com)
  • Based on these data, we now know that KYPROLIS not only significantly extended progression-free survival compared to Velcade, but also overall survival, making it a clinically meaningful advance in the treatment of relapsed or refractory multiple myeloma. (amgen.com)
  • A survival benefit has rarely been demonstrated in relapsed or refractory multiple myeloma. (amgen.com)
  • FDA granted accelerated approval to Elrexfio (elranatamab-bcmm) for adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy. (pharmtech.com)
  • The treatment is approved for adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-cluster of differentiation 38 monoclonal antibody. (pharmtech.com)
  • Combination therapies, in particular those using 3 and 4 drugs, have improved response rates and survival outcomes for patients with relapsed or refractory multiple myeloma. (onclive.com)
  • That's a very impressive PFS for a triplet therapy in relapsed or refractory multiple myeloma. (onclive.com)
  • Oncopeptides AB), an alkylating drug, for the treatment, in combination with dexamethasone, of adults with relapsed or refractory multiple myeloma who have received ≥4 lines of therapy and whose disease is triple-refractory to ≥1 proteasome inhibitors, 1 immunomodulatory drug, and 1 CD-38-directed monoclonal antibody. (ahdbonline.com)
  • Of 157 patients with relapsed or refractory multiple myeloma, 97 patients had triple-refractory disease and had received ≥4 lines of therapy. (ahdbonline.com)
  • report the initial toxicity profile of a BCMA-directed cellular immunotherapy for patients with relapsed or refractory multiple myeloma. (massgeneral.org)
  • NICE is unable to make a recommendation on teclistamab (Tecvayli) for treating relapsed or refractory multiple myeloma after 3 or more therapies in adults. (bvsalud.org)
  • This suggests that for eligible patients that progress after BCMA-directed CAR T, additional T-cell-engaging therapies contribute meaningfully to survival and that T-cell activation is feasible down the line," Parekh and team wrote. (medpagetoday.com)
  • In explaining the rationale for the study, Parekh and colleagues noted that while the use of BCMA-directed CAR T-cell therapies in relapsed and refractory multiple myeloma have demonstrated high response rates, optimal treatment regimens have yet to be defined for patients who relapse. (medpagetoday.com)
  • [1] Yet fast forward to today and we're seeing some blood cancer patients reach 10 years of remission thanks to a whole array of new, breakthrough therapies, coupled with a deeper understanding of the mechanisms of disease. (janssen.com)
  • novel therapies and regimens have also led to improved patient outcomes in first-line treatment of multiple myeloma (MM) and greater flexibility for clinicians to make treatment decisions based on the unique needs of each patient. (janssen.com)
  • Gracell Biotechnologies Inc. ("Gracell") is a global clinical-stage biopharmaceutical company dedicated to discovering and developing breakthrough cell therapies for the treatment of cancers and autoimmune diseases. (biospace.com)
  • antibody-drug conjugates, immune checkpoint therapy, adoptive cell therapies such as natural killer cells, marrow infiltrating lymphocytes, dendritic cells, CAR T cell therapies and cancer vaccines represent the basis for next generation myeloma therapies. (trialx.com)
  • While multiple myeloma care and outcomes have improved, the disease remains incurable and patients like the ones in the KarMMa study, whose cancer has progressed despite treatment with at least three previous therapies, face poor survival rates. (lls.org)
  • While the disease is considered incurable, and the relative five-year survival rate for patients diagnosed with multiple myeloma in the US is approximately 50%, the addition of multiple new FDA-approved therapies to treat the disease are likely to increase overall survival rates in the future. (lls.org)
  • Promising clinical results with cellular therapies for patients with blood cancers highlight advances being presented by researchers from The University of Texas MD Anderson Cancer Center at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting . (mdanderson.org)
  • All patients had R/R disease after receiving up to five therapies, and all had received previous Bruton's tyrosine kinase (BTK) inhibitor therapy. (mdanderson.org)
  • Patients with multiple myeloma suffer from disease-related complications such as bone destruction, toxicities from repeated therapies and age-related co-morbidities. (nih.gov)
  • This booklet describes current therapies for myeloma as well as emerging treatment options that are being tested in clinical trials. (themmrf.org)
  • This activity has been developed to present and discuss current recommended strategies for individualizing treatment plans for patients with RRMM by incorporating the most up-to-date clinical evidence on sequencing small molecule-based therapies and BCMA-targeted therapies that achieve durable remission while minimizing toxicity. (themmrf.org)
  • it was approved in March 2022 by the US Food and Drug Administration for use in patients with refractory/relapsed multiple myeloma who have already tried four or more therapies. (medscape.com)
  • Newly diagnosed cancer patients are frequently found suffering from a metastatic disease, which poses additional challenges to the delivery of effective therapies. (cambridge.org)
  • Effect of Targeted RA Therapies on Inflammation and Anemia In what ways do various targeted DMARDs impact systemic inflammation and anemia in patients with rheumatoid arthritis? (medscape.com)
  • This impressive lineup of targeted therapies predicts for a brighter future for patients with this currently incurable malignancy. (cancernetwork.com)
  • Mass General Cancer Center is an authorized treatment center for FDA approved CAR T-cell therapies for adult patients with lymphoma and adult patients with multiple myeloma. (massgeneral.org)
  • Billy Costa talks with Dr. Matt Frigault and oncology social worker Lauren DeMarco to learn more about the latest in CAR- T-cell therapies and what it all means for patients. (massgeneral.org)
  • Triple-negative cancers are so called because they do not express receptors for the hormones estrogen and progesterone, or for HER2 (human epidermal growth factor 2), and hence patients with these cancers are not candidates for treatment with modern hormonal therapies or the highly effective HER2-targeted drug Herceptin (trastuzumab). (ucsf.edu)
  • Several drug therapies are valuable in the treatment of symptomatic MM. Clinicians treat many patients with high-dose therapy and peripheral blood or bone marrow stem cell transplantation. (medscape.com)
  • 7,8] This eventually led to large phase III trials of thalidomide and dexamethasone in the setting of relapsed as well as newly diagnosed myeloma and its approval for use in this disease. (cancernetwork.com)
  • Frailty score predicts outcome in transplant-ineligible patients with newly diagnosed myeloma and is incorporated into the staging criteria. (medscape.com)
  • Treatment of newly diagnosed myeloma. (medscape.com)
  • Multiple myeloma (MM) represents 1% of all cancers and is the second most common hematologic malignancy, after lymphoma. (scielo.br)
  • Since then, we've reached a point where multiple treatment options exist across the spectrum of blood cancers. (janssen.com)
  • While treatments for solid cancers have leapt forward with precision medicine, allowing us to prescribe treatments to patients displaying specific biomarkers, MM lacks specific response predicting biomarkers that have proven successful in novel treatments for cancers such as prostate or lung. (janssen.com)
  • GC012F is currently being evaluated in clinical studies in multiple hematological cancers as well as autoimmune diseases, and has demonstrated a consistently strong efficacy and safety profile. (biospace.com)
  • The discussion highlighted the opportunity that these engineered immune cells present to cancer treatment and possible use in treatment of other cancers. (trialx.com)
  • As part of our mission to eliminate cancer, MD Anderson researchers conduct hundreds of clinical trials to test new treatments for both common and rare cancers. (mdanderson.org)
  • Of all the other cancers, multiple myeloma causes this complication the most. (webmd.com)
  • A link between visual function, ocular symptoms, and quality of life was found in cross-sectional study of patients who underwent radiotherapy for head and neck cancers, according to a presentation at the 2018 ONS Annual Congress. (oncologynurseadvisor.com)
  • Karmanos' BMT program is one of the largest in the country with numerous options for treating multiple myeloma and other cancers of blood-forming organs. (karmanos.org)
  • Early Mortality in ICI-Treated Cancers in Routine Practice A better understanding of the predictors of early mortality among cancer patients treated with ICIs could help guide treatment selection. (medscape.com)
  • The Emerging Role for CAR T Cells in Solid Tumor Oncology Learn more about the exciting potential role of CAR T cells in the targeted treatment of solid tumor cancers. (medscape.com)
  • New Medicines and De Novo Metastatic Cancer Survival Changes What impact have newly approved treatment options had on the survival of patients with de novo metastatic cancers? (medscape.com)
  • Meanwhile, a series of projects focused on specific therapeutic areas are putting the concept of 'big data for better outcomes' into practice in the fields of cardiovascular disease, haematological malignancies (blood cancers), Alzheimer's disease, and prostate cancer. (europa.eu)
  • The Institute's multiple myeloma related research is far-reaching and benefits all cancers where bone metastasis is a threat. (kron4.com)
  • MMRF said it hopes that the initiative leads not only to new, targeted therapeutics for multiple myeloma, but also for other cancers. (genomeweb.com)
  • CHICAGO and RARITAN, NJ, June 4, 2017 - Janssen Research & Development, LLC today announced new data from updated analyses of the pivotal Phase 3 CASTOR and POLLUX clinical studies, demonstrating that DARZALEX ® (daratumumab) in combination with bortezomib and dexamethasone, or lenalidomide and dexamethasone, improved progression-free survival (PFS) and the overall response rate (ORR) for previously-treated patients with multiple myeloma, regardless of cytogenetic risk. (jnj.com)
  • Additionally, data from the Phase 1b MMY1001 study will show the potential of daratumumab in combination with carfilzomib, lenalidomide and dexamethasone (KRd) for newly diagnosed patients with multiple myeloma. (jnj.com)
  • Nearly all patients received an immunomodulatory compound, a proteasome inhibitor and dexamethasone. (confex.com)
  • Design and Methods Oral cyclophosphamide, thalidomide, and dexamethasone was compared with infusional cyclophosphamide, vincristine, doxorubicin, and dexamethasone in patients with newly diagnosed multiple myeloma. (haematologica.org)
  • A trend toward an overall survival advantage for cyclophosphamide-thalidomide-dexamethasone over cyclophosphamide-vincristine-doxorubicin-dexamethasone was also observed in a subgroup of patients with favorable interphase fluorescence in situ hybridization. (haematologica.org)
  • Conclusions The cyclophosphamide-thalidomide-dexamethasone regimen showed improved response rates and was not inferior in terms of survival outcomes to the standard infusional regimen of cyclophosphamide-vincristine-doxorubicin-dexamethasone. (haematologica.org)
  • Combination vincristine, doxorubicin, and dexamethasone (VAD) is considered a standard infusional induction therapy for younger MM patients prior to HDT and ASCT. (haematologica.org)
  • Patients received treatment until progression with KYPROLIS as a 30-minute infusion on days 1, 2, 8, 9, 15 and 16 of 28 day treatment cycles, along with low-dose dexamethasone (20 mg). (amgen.com)
  • Patients who received bortezomib (1.3 mg/m 2 ) with low-dose dexamethasone (20 mg) were treated with bortezomib administered subcutaneously or intravenously at the discretion of the investigator and in accordance with regional regulatory approval of bortezomib. (amgen.com)
  • We assessed the outcomes of pomalidomide and dexamethasone treatment in relapsed/refractory multiple myeloma (RRMM) patients with ?1 prior line of therapy. (muni.cz)
  • We analyzed the data of all RRMM patients treated with pomalidomide and dexamethasone at nine Czech centers between 2013 and 2018. (muni.cz)
  • In an updated analysis of the phase III MAIA trial, the addition of daratumumab to lenalidomide and dexamethasone resulted in a statistically significant overall survival benefit over lenalidomide/dexamethasone alone in patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant. (ascopost.com)
  • These results strongly support upfront daratumumab with lenalidomide and dexamethasone (D-Rd) as a new standard of care for patients with transplant-ineligible newly diagnosed multiple myeloma," Dr. Facon said. (ascopost.com)
  • In both arms, patients received lenalidomide at 25 mg on days 1 to 21 of each cycle and dexamethasone at 40 mg weekly. (ascopost.com)
  • For patients who experience early relapse, data from the phase 3 IKEMA study (NCT03275285) supported the use of isatuximab-irfc (Sarclisa), a CD38-directed cytolytic antibody, plus carfilzomib (Kyprolis) and dexamethasone (Isa-Kd) in patients who received 1 to 3 prior lines of therapy. (onclive.com)
  • NCT01568866], which [evaluated] Kd compared with bortezomib [Velcade] and dexamethasone, that the PFS was approximately 18 months for patients treated with Kd. (onclive.com)
  • PFS was 11.8 months for the 211 patients assigned to receive standard of care, which consisted of the physician's choice of either pomalidomide, bortezomib, and dexamethasone (PVd), or daratumumab, pomalidomide, and dexamethasone (DPd). (medscape.com)
  • Patients received intravenous melphalan flufenamide 40 mg on day 1 and oral dexamethasone 40 mg on days 1, 8, 15, and 22 of every 28-day cycle, until disease progression or until unacceptable toxicity. (ahdbonline.com)
  • Patients taking three drugs -- carfilzomib, lenalidomide and dexamethasone -- stayed free of disease progression for 26 months on average," he says. (sciencedaily.com)
  • Researchers found that adding carfilzomib to standard treatment (lenalidomide and dexamethasone) resulted in 8.7 months of longer remission, almost 50 percent longer than the standard two-drug combination (26.3 months versus 17.6 months). (sciencedaily.com)
  • Takeda is also presenting key insights from the US MM-6 trial, which investigates the effectiveness and safety of an in- class transition to oral NINLARO in combination with lenalidomide and dexamethasone in newly diagnosed multiple myeloma patients who have previously received a parenteral bortezomib-based triplet induction therapy. (takeda.com)
  • All transplant-eligible multiple myeloma patients should receive a triplet induction therapy (immunomodulatory agents, proteasome inhibitor and dexamethasone). (medscape.com)
  • [ 1 ] Although the combination of carfilzomib (second-generation proteasome inhibitor) with lenalidomide and dexamethasone showed higher efficacy in phase II trials, particularly in high-risk patients, interim analysis in an ongoing phase III clinical trial showed that progression-free survival (PFS) was not superior to that with bortezomib/lenalidomide/dexamethasone. (medscape.com)
  • GC012F demonstrated a 100% overall response rate (ORR) and a 100% MRD- sCR rate among 19 transplant-eligible, high-risk NDMM patients as of the data cutoff date of August 1, 2023. (biospace.com)
  • Pfizer announced that FDA has granted accelerated approval to its multiple myeloma treatment, Elrexfio (elranatamab-bcmm), on Aug. 14, 2023. (pharmtech.com)
  • Final results of CARTITUDE-1, reported in a scientific poster at ASCO 2023, showed that almost half of patients (47.5%) who were treated with cilta-cel were free of disease progression at 3 years, and 59.8% had sustained, complete responses. (medscape.com)
  • Although multiple myeloma patients younger than 66 years of age have an aggressive presentation, this did not translate into an inferior overall survival, particularly in those undergoing autologous hematopoietic stem cell transplantation. (scielo.br)
  • Background Thalidomide is active in multiple myeloma and is associated with minimal myelosuppression, making it a good candidate for induction therapy prior to high-dose therapy with autologous stem-cell transplantation. (haematologica.org)
  • High-dose therapy (HDT) combined with autologous stem-cell transplantation (ASCT) provides superior response and survival outcomes versus standard chemotherapy in patients with newly diagnosed (ND) multiple myeloma (MM). 1 , 2 Standard induction chemotherapy regimens, however, are often associated with hematologic stem-cell toxicity, which may compromise the collection of stem cells for ASCT. (haematologica.org)
  • 2010 Application of HLA-A*0201/WT1 pentamer combined with intracellular IFNgamma+ staining in detecting circulating WT1 specific T cells in leukemia 2010 "Comparison of Wilms' tumor antigen 1-specific T lymphocyte generation soon after nonmyeloablative allergenic stem-cell transplantation in acute and chronic leukemia patients", published in Int J Hematol. (wikipedia.org)
  • 2009 Changes of lymphocyte subsets in acute leukemia patients after HLA-mismatched nonmyeloablative hematopoietic stem cell transplantation 2010 "Efficacy of bone marrow-derived mesenchymal stem cells in the treatment of sclerodermatous chronic graft-versus-host disease: clinical report", published in Biol Blood Marrow Transplant 2009 A modified haploidentical nonmyeloablative transplantation without T cell depletion for high-risk acute leukemia: successful engraftment and mild GVHD" published in Biol Blood Marrow Transplant. (wikipedia.org)
  • Although treatment strategies changed from traditional chemotherapy and autologous hematopoietic stem cell transplantation to novel targeted drug therapy, the outcome was not improved ( 2 ). (spandidos-publications.com)
  • Autologous Stem Cell Transplantation (ASCT) remains the standard of care for newly diagnosed, eligible patients. (themmrf.org)
  • Presentations are available online starting Friday, June 12, 2020, and include positive results from TOURMALINE-MM4, a Phase 3, randomized clinical trial evaluating the effect of single-agent oral NINLARO ™ (ixazomib) as a first-line maintenance therapy in adult patients diagnosed with multiple myeloma who had not been treated with stem cell transplantation. (takeda.com)
  • In general, the first decision made in the management of patients with myeloma who require systemic therapy is whether stem cell transplantation is part of the strategy. (medscape.com)
  • Role of autologous and allogeneic stem cell transplantation in myeloma. (medscape.com)
  • Participants within 12 months from initiation of induction therapy who achieved at least a partial response (PR) after autologous stem cell transplantation (ASCT) with or without consolidation, according to International Myeloma Working Group (IMWG 2016) criteria. (who.int)
  • Hematopoietic stem cell transplantation (HSCT) affects serious risks for the patient, including death. (bvsalud.org)
  • Studies showed that Black patients were less likely to initiate timely novel therapy and to be treated with more effective regimens, were half as likely to undergo ASCT, and were referred to ASCT later in the disease course compared to White patients. (lls.org)
  • Conventional medical treatment for these patients includes pain medication, activity limitation, physical therapy, and (possibly) bracing. (medscape.com)
  • Patients with multiple myeloma who relapse after treatment with B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell therapy can be salvaged with multiple lines of therapy, a retrospective study suggested. (medpagetoday.com)
  • Among 79 patients who were given a total of 237 salvage treatments, median overall survival (OS) from the date of relapse post-CAR T-cell therapy was 17.9 months (95% CI 14.0 to not estimable [NE]), reported Samir Parekh, MD, of the Icahn School of Medicine at Mount Sinai in New York City, and colleagues. (medpagetoday.com)
  • Of note, patients who received a T-cell-engaging therapy (a bispecific antibody or subsequent CAR T-cell therapy) had the greatest success in this setting, with OS not reached after a median follow-up of 21.3 months, they noted in Blood . (medpagetoday.com)
  • Patients with multiple myeloma who relapse after BCMA-directed CAR T have a limited prognosis but can be potentially treated with multiple lines of salvage therapy," they wrote. (medpagetoday.com)
  • Achieving a partial response or better with the first line of salvage therapy was associated with a significantly longer median OS of 29.9 months compared with 14.6 months for patients who did not achieve an objective response ( P =0.028). (medpagetoday.com)
  • The 13 patients who received a T-cell-engaging therapy immediately after relapse on CAR T had an ORR of 75.0% and a median PFS of 9.1 months. (medpagetoday.com)
  • From March 2017 to January 2022, 140 patients with multiple myeloma were treated with a BCMA-directed CAR T-cell therapy on a clinical trial at either the Mount Sinai Tisch Cancer Institute or Memorial Sloan Kettering Cancer Center in New York City. (medpagetoday.com)
  • The 79 patients included in this analysis had a median age of 60 years at the time of progression after CAR T-cell therapy, and 60% were men. (medpagetoday.com)
  • Based on its oral administration and the reduced incidence of infection and cytopenia, cyclophosphamide-thalidomide-dexa-methasone may be considered an effective induction therapy option for patients with newly diagnosed multiple myeloma. (haematologica.org)
  • [5] In cancer, biomarkers are abnormalities or mutations found in cancer cells that can be used to detect and identify different types of cancer, predict the probable course of the disease, including its recurrence, and help guide treatment decisions by providing insights into patients likely response to a therapy. (janssen.com)
  • These results further support KYPROLIS as a foundational therapy in this patient population. (amgen.com)
  • GC012F is Gracell's FasTCAR-enabled BCMA/CD19 dual-targeting autologous CAR-T cell therapy, which aims to transform cancer and autoimmune disease treatment by driving fast, deep and durable responses with improved safety profile. (biospace.com)
  • FDA approval of the breakthrough CAR-T cell therapy for cancer brings the first approved gene therapy treatment to the United States. (trialx.com)
  • In 2017 stem cell transplants remains a key option for treatment of eligible multiple myeloma patients, and in majority of patients it is done as a part of frontline therapy. (trialx.com)
  • Researchers believe that MRD testing could help them compare myeloma therapy strategies, evaluate new treatments faster, and guide treatment decisions. (trialx.com)
  • The known side-effects for CAR T therapy were reported for ide-cel with marked cytokine release syndrome (CRS) and CAR T cell-associated neurotoxicity, occurring in 85% and 28% of patients, respectively, both of which were usually transient. (lls.org)
  • This therapy achieved reasonable outcomes comparable to the data from clinical trials even though this was an unbiased cohort of patients. (muni.cz)
  • These findings include long-term outcomes of patients receiving an infusion of brexucabtagene autoleucel (KTE-X19) for mantle cell lymphoma, efficacy of gamma delta CAR T therapy for aggressive B-cell lymphoma and responses of umbilical cord blood-derived expanded natural killer cells when given together with combination therapy before stem cell transplant. (mdanderson.org)
  • Three-year follow-up data from the Phase II ZUMA-2 trial showed a long-term survival benefit and low disease relapse potential with one infusion of the anti-CD19 chimeric antigen receptor (CAR) T cell therapy brexucabtagene autoleucel (KTE-X19) in patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL). (mdanderson.org)
  • This represents the longest follow-up of CAR T cell therapy in patients with mantle cell lymphoma to date," Wang said. (mdanderson.org)
  • It is encouraging to see this therapy induced durable long-term responses and a low relapse rate for these patients. (mdanderson.org)
  • The findings support future study of CD19-directed CAR T cell therapy in patients with high-risk MCL in earlier treatment lines. (mdanderson.org)
  • According to the press release, data from the Phase II study showed meaningful responses among heavily pretreated RRM patients who received elranatamab-bcmm as their first BCMA-directed therapy. (pharmtech.com)
  • Among patients who received four or more lines of therapy prior to elranatamab-bcmm, overall response rate was 58%, with 82% maintaining the response for at least nine months. (pharmtech.com)
  • Discovered at Pfizer, we advanced this therapy from a first-in-patient trial to approval in less than five years, because we know that time is life for people living with multiple myeloma," said Angela Hwang, chief commercial officer and president, Global Biopharmaceuticals Business, Pfizer, in the release. (pharmtech.com)
  • Most multiple myeloma patients will experience relapse or resistance of their disease to treatment, often facing increased symptom burden and lowering their chance of surviving longer with each attempted line of therapy," said Ajay Nooka, director of the Multiple Myeloma Program at Winship Cancer Institute of Emory University and MagnetisMM clinical trial investigator, in the release. (pharmtech.com)
  • Analysis of a cohort of patients with newly diagnosed multiple myeloma focused on the effect of post-ASCT maintenance therapy on health-related QOL and clinical outcomes. (oncologynurseadvisor.com)
  • The benefits are all the more meaningful because the study population was elderly-99% were age 65 or older, and 44% were aged 75 to 90, said Dr. Facon, who emphasized that half or more of nontransplant elderly patients never receive subsequent therapy. (ascopost.com)
  • This webcast features evidence-based presentations along with patient cases designed to address the nuances of T cell-activating therapy use, identification of patients that are the best candidates for these approaches, and options for patients who may not be candidates for this therapy. (themmrf.org)
  • There's a study from Germany that looked at 40 centers and the quality-of-life outcomes across several lines of therapy. (pharmacytimes.com)
  • CHICAGO - Lenalidomide (Revlimid) is a vital component of early therapy and maintenance for patients with multiple myeloma, but patients in first relapse who have disease that is refractory to lenalidomide have few good options for subsequent lines of therapy and a generally poor prognosis. (medscape.com)
  • In addition, the median PFS was longer than for any previously reported therapy for heavily pretreated patients with relapsed/refractory multiple myeloma, the authors said. (medscape.com)
  • For the CARTITUDE-4 trial, the investigators enrolled patients aged 18 years or older with lenalidomide-refractory multiple myeloma who had experienced relapse after one to three prior lines of therapy that included a prosteasome inhibitor and immunomodulator. (medscape.com)
  • Identifying preventable factors of reduced response to therapy would translate into better care of cancer patients. (cambridge.org)
  • Less certainty exists on the role of nutrition therapy in improving cancer patients' body composition and clinical outcome. (cambridge.org)
  • When part of early palliative care, nutrition therapy improves cancer patients' quality of life and may prolong survival at a fraction of the costs of developing new drugs. (cambridge.org)
  • Patients had a median of 5 (range 3-14) prior lines of therapy. (advfn.com)
  • Impact of Antibiotic Exposure Before ICIs on Cancer Survival These findings highlight the importance of considering prior antibiotic use before initiating ICI therapy in cancer patients. (medscape.com)
  • A number of these new agents have demonstrated significant activity in patients with MM. Over the past 5 years, three drugs have received approval from the US Food and Drug Administration for therapy in MM—bortezomib, thalidomide, and lenalidomide. (cancernetwork.com)
  • The past decade has witnessed the most dramatic improvement in the treatment of multiple myeloma since the introduction of melphalan (Alkeran) and prednisone in the 1960s and high-dose therapy in the 1980s. (cancernetwork.com)
  • Later relapse (fourth, fifth, and beyond) means that multiple lines of therapy have already been tried. (healthline.com)
  • Because of expanded drug therapy options and treatment combinations, IMBCR provides patients with an opportunity to enhance their chances of surviving cancer and conquer one of the hardest challenges of their lives. (kron4.com)
  • CAR T therapy is a highly effective treatment for myeloma patients, even in highly relapsed multiple myeloma. (player.fm)
  • Doris K. Hansen, MD, discussed results of an efficacy analysis examining the BCMA-directed CAR T-cell therapy idecabtagene vicleucel in real-world treatment of patients with relapsed/refractory multiple myeloma. (cancernetwork.com)
  • This multicenter retrospective study of real-world outcomes demonstrated comparable efficacy and toxicity in patients commercially treated with idecabtagene vicleucel vs those treated with the same therapy in the KarMMa-1 trial, even though 77% would have been ineligible for inclusion in the trial. (cancernetwork.com)
  • It's important to note that 77% [n = 150] of this patient population would have been ineligible for participation in the KarMMA-1 trial, most commonly due to prior exposure to BCMA-targeted therapy, organ dysfunctions like renal insufficiency, poor performance status, and cytopenias. (cancernetwork.com)
  • We identified on a multivariable model that patients previously exposed to BCMA-targeted therapy experienced inferior outcomes, which impacted rates of complete response and PFS. (cancernetwork.com)
  • Kiss 108 FM's Billy Costa talks with four experts from the Mass General Cancer Center to learn about what CAR T-cell therapy is and what impact it has on both patients and the medical community. (massgeneral.org)
  • The approval of new drugs continues to change the landscape of myeloma maintenance therapy. (medscape.com)
  • Alkylator and nitrosourea therapy is usually deferred or reduced in patients who may require autologous stem cell collection, to avoid injury to the stem cells. (medscape.com)
  • Patients who present with active (symptomatic) multiple myeloma are treated with induction therapy. (medscape.com)
  • The presentation of MM can range from asymptomatic to severely symptomatic, with complications requiring emergent treatment. (medscape.com)
  • In addition, adverse event reports submitted to FDA showed severe and symptomatic hypocalcemia, including hospitalization and death, is occurring in patients with advanced kidney disease treated with Prolia. (medlineplus.gov)
  • Preliminary results from a separate internal FDA study investigating the risk of hypocalcemia suggest that patients on dialysis treated with Prolia are at substantial risk for severe and symptomatic hypocalcemia, including hospitalization and death. (medlineplus.gov)
  • OBJECTIVES: The objectives of this article are to determine: (1) the prevalence of low bone mineral density (BMD) and factors associated with low BMD and (2) the prevalence of symptomatic fragility fractures in inception patients of the Toronto Lupus Cohort (TLC). (who.int)
  • They also pointed out that all of the patients in the study had enrolled in clinical trials, and that "potential trial selection criteria may have introduced a deviation between enrolled patients and the real-world population. (medpagetoday.com)
  • Dr. Browning serves as the Principal Investigator on several clinical trials here at Yale for patients with multiple myeloma and AL amyloidosis and is interested in design of new clinical trials to further help her patients and others living with these diseases. (yale.edu)
  • Currently, decisions on treatments and pricing are based largely on data from clinical trials. (europa.eu)
  • The Multiple Myeloma Research Foundation provides educational programs to help people with myeloma, family members, caregivers, and healthcare professionals learn more about the disease and today's most promising treatment options, including clinical trials, from leading multiple myeloma doctors and researchers. (player.fm)
  • The findings are particularly noteworthy because drugs that act on the newly discovered target, a protein known as PIM1, are already in clinical trials for leukemia and multiple myeloma. (ucsf.edu)
  • The data include longer-term follow-up from the initial 16 patients, for whom early results were presented at the 2022 American Society for Hematology (ASH) Annual Meeting, plus three additional patients enrolled and treated. (biospace.com)
  • As of the December 9, 2022 data cut-off, patients received a median of 4 (range 1-20) cycles of the combination and a median of 3 (range 1-9) monotherapy cycles. (advfn.com)
  • Treatment of Metastatic Uveal Melanoma in 2022 Recent developments in our understanding of metastatic uveal melanoma and treatment advancements have improved the prognosis of these patients. (medscape.com)
  • These compelling findings from the Phase 3 CASTOR and POLLUX trials show daratumumab delivered deep and durable responses for previously-treated patients, regardless of cytogenetic risk," said Dr. Katja Weisel, Associate Professor, Department of Hematology and Oncology, University Hospital of Tuebingen, Tuebingen, Germany. (jnj.com)
  • He sought treatment at the Karmanos Cancer Center, where he met with Dr. Zonder, leader of the Multiple Myeloma and Amyloidosis Multidisciplinary Team (MDT) and member of the Hematology Oncology MDT. (karmanos.org)
  • CancerTherapyAdvisor.com is a free online resource that offers oncology healthcare professionals a comprehensive knowledge base of practical oncology information and clinical tools to assist in making the right decisions for their patients. (cancertherapyadvisor.com)
  • How Being a Member of Diverse Communities May Impact Your Access to Oncology Care, Treatment, Management of Treatment Side Effects & Pain Management - What to Expect from Your Relationship with Your Health Care Team: Is Your Health Care Team Providing You with Equitable, Excellent Care? (player.fm)
  • Mass General Cancer Center's Dr. Nir Hacohen sits down with Kiss 108's Billy Costa to discuss a researchers perspective of immuno-oncology and how it has impacted patients. (massgeneral.org)
  • NCCN Clinical Practice Guidelines in Oncology, Multiple Myeloma Version 3.2016. (medscape.com)
  • The LLS mission: Cure leukemia, lymphoma, Hodgkin disease and myeloma, and improve the quality of life of patients and their families. (lls.org)
  • While the exact cause of multiple myeloma is not clear, there are several factors that may influence a person's risk of developing the disease, including age, sex, race, and medical history. (aacr.org)
  • The risk of multiple myeloma increases as a person gets older, and the disease is more common in men, African Americans, and in those who have certain premalignant conditions. (aacr.org)
  • Individuals who have an increased risk for multiple myeloma may be monitored for signs of the disease, but it is not currently possible to prevent the development of multiple myeloma. (aacr.org)
  • Furthermore, deleting one copy of miR15a/miR16-1 in mice with multiple myeloma significantly enhanced the aggressiveness of their disease and led to increased expression of genes that promote cellular proliferation. (aacr.org)
  • Studies like the one described above help researchers understand disease progression and could eventually lead to advances in detection and treatment. (aacr.org)
  • Multiple myeloma is a disease of the elderly. (scielo.br)
  • For an incurable disease like multiple myeloma, a major treatment goal for oncologists and hematologists is to help patients live as long as possible," said study co-author and investigator Meletios A. Dimopoulos, M.D., professor of Clinical Therapeutics at the National and Kapodistrian University of Athens , School of Medicine. (amgen.com)
  • The primary endpoint of the trial was PFS, defined as the time from treatment initiation to disease progression or death. (amgen.com)
  • Research shows that stem cell transplants significantly increases the amount of time, for which a patient has their disease under control. (trialx.com)
  • More than 30,000 adults will be diagnosed with multiple myeloma this year, according to the Centers for Disease Control and Prevention. (ascopost.com)
  • That is why it is important for Black Americans to learn about the early symptoms of myeloma and let their doctors know they are at higher risk for the disease. (ascopost.com)
  • The project launch includes the debut of a dedicated M-Power Charlotte website, which will help people to familiarize themselves with the symptoms of the disease and the latest treatments. (ascopost.com)
  • Overall, 16.5% of patients had a minimal response, and 32.3% had stable disease /progression. (muni.cz)
  • BTK inhibitors have greatly improved outcomes in R/R MCL, yet patients who have subsequent disease progression are likely to have poor outcomes, with median overall survival of just six to 10 months. (mdanderson.org)
  • The researchers also evaluated minimal residual disease (MRD) as an exploratory endpoint using next-generation sequencing on 29 patients. (mdanderson.org)
  • Guo Mei brings her passion and knowledge for treating blood disease with microtransplantation in 307th Hospital, and with an equally dedicated medical and support team, works hard every day to improve the quality of lives of the patients. (wikipedia.org)
  • 2011 Expression of NOV and BNIP3 gene in mouse myelomonocytic leukemia and its significance 2011 Relationship between WT1-specific T-cell subsets and graft-versus-host disease after nonmyeloablative allogeneic transplantation 2011 "WT1-specific CTL cells of recipient origin may exist in the peripheral blood of patients achieving full donor chimerism soon after nonmyeloablative transplantation", published on Clin Transplant. (wikipedia.org)
  • Therefore, the identification of mechanisms underlying the regulation of the malignant behavior of MM and key genes in disease progression has the greatest significance for the establishment of novel therapeutic strategies and improvement of the prognosis in patients. (spandidos-publications.com)
  • No prior malignancy is allowed except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer for which the patient has been disease free for at least three years. (knowcancer.com)
  • Nine patients had disease progression and were referred safely back to face-to-face clinics. (nih.gov)
  • With significant responses in a patient population with highly refractory disease, we believe [elranatamab-bcmm] is poised to potentially become the new standard of care for multiple myeloma, as we plan to build upon this indication with continued development across the … MagnetisMM program. (pharmtech.com)
  • We work closely with you to build a treatment plan that meets your needs, while fighting the disease and preserving your quality of life. (bannerhealth.com)
  • Be assured that the doctors at Banner MD Anderson are at the forefront of research into better treatments and outcomes for this unusual disease. (bannerhealth.com)
  • While there's no way to prevent the disease, knowing the symptoms and talking to your doctor if you have concerns can help you catch it early, when treatment is most successful. (bannerhealth.com)
  • Symptoms of multiple myeloma may not present until later stages of the disease. (bannerhealth.com)
  • Using 2 established sexual function questionnaires, researchers evaluated the effect of breast cancer treatment on sexual quality of life for survivors of the disease. (oncologynurseadvisor.com)
  • While patient survival has improved over the past 20 years, the disease is incurable. (karmanos.org)
  • Patients continued treatment until disease progression. (ascopost.com)
  • This booklet is designed to help patients with multiple myeloma - and their friends, families, and caregivers - better understand this disease: what myeloma is and how it develops within the body. (themmrf.org)
  • Patients with multiple myeloma typically have a preceding phase of disease in which there are changes in the bone marrow but no symptoms or organ damage. (themmrf.org)
  • Patients with lenalidomide-refractory multiple myeloma who received a single infusion of ciltacabtagene autoleucel demonstrated a 74% reduction in the risk for disease progression or death compared with patients who received the standard of care. (medscape.com)
  • Also commenting on the new results, ASCO Expert Oreofe Odejide, MD, of the Dana-Farber Cancer Institute in Boston, said in a statement: "Lenalidomide has become a foundation of care for people with myeloma, but as its use has expanded, so has the number of patients whose disease will no longer respond to the treatment. (medscape.com)
  • Research has shown melphalan flufenamide to be a novel and innovative therapeutic option, which is active in refractory disease and has manageable toxicity, with the convenience of being administered by infusion once a month," said Paul G. Richardson, MD, Director of Clinical Research at the Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute. (ahdbonline.com)
  • Interim analysis of the ASPIRE clinical trial, which enrolled 792 patients with relapsed multiple myeloma from 20 countries, found an "unprecedented" prolongation of the time patients were free of disease progression, says the study's lead investigator, Keith Stewart, M.B., Ch.B, a Mayo Clinic oncologist in Arizona. (sciencedaily.com)
  • The number of patients who responded to treatment was also significantly improved by adding carfilzomib to standard treatment -- 87.4 percent versus 66.9 percent -- and more than three times more patients had no detectable disease after the three-drug treatment (31.8 percent versus 9.3 percent). (sciencedaily.com)
  • Our better understanding of the complex interaction of multiple myeloma (MM) cells with their bone marrow microenvironment and the signaling pathways that are dysregulated in this process has resulted in a dramatic increase in the therapeutic agents available for this disease. (cancernetwork.com)
  • This was followed by the introduction of the proteasome inhibitor bortezomib (Velcade), which has shown remarkable efficacy in the treatment of myeloma, both relapsed refractory and newly diagnosed disease. (cancernetwork.com)
  • The authors have reviewed the various classes of novel drugs that are being evaluated in the setting of myeloma based on their mechanisms as well as the current understanding of disease biology. (cancernetwork.com)
  • 3. Sarasquete ME, Garcia-Sanz R, Gonzalez D, et al: Minimal residual disease monitoring in multiple myeloma: A comparison between allelic-specific oligonucleotide real-time quantitative polymerase chain reaction and flow cytometry. (cancernetwork.com)
  • Patients who received denosumab had a significant improvement in disease-free survival and bone metastasis-free survival. (cancertherapyadvisor.com)
  • You can enter several periods of remission with multiple myeloma during the disease. (healthline.com)
  • This data is inevitably limited in scope and does not fully reflect the situation of all patients with a given disease. (europa.eu)
  • Minimal Residual Disease (MRD) testing is a more sensitive way to test for remaining disease following myeloma treatment. (player.fm)
  • A team of researchers led by UC San Francisco scientists has identified a new drug target for triple-negative breast cancer, an aggressive disease subtype that has the poorest outcomes and accounts for as many as one in five cases. (ucsf.edu)
  • I'm a breast oncologist, and I've seen too many patients die from triple-negative disease," said senior author Andrei Goga , MD, PhD, professor of cell and tissue biology and of medicine at UCSF, and a member of the Helen Diller Family Comprehensive Cancer Center. (ucsf.edu)
  • In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms. (genomeweb.com)
  • This case illustrates the need to better define the geo- Management of Patients with graphic extent and modes of transmission of this debilitat- ing disease so that primary control measures can be iden- Candida auris Fungemia at tified. (cdc.gov)
  • Most patients came from nursing homes, and more disease: a systematic review. (cdc.gov)
  • Minimal residual disease testing of the bone marrow is incorporated into the response evaluation to further determine disease burden in patients who achieve complete remission. (medscape.com)
  • The NCCN recommends that a patient whose bone survey is negative should be assessed for bone disease with whole-body MRI or PET/CT. (medscape.com)
  • Myeloma today: Disease definitions and treatment advances. (medscape.com)
  • When patients and vaccine providers § engage in shared clinical decision-making for PCV13 use to determine whether PCV13 is right for a particular person, considerations might include both the person's risk for exposure to PCV13 serotypes and their risk for developing pneumococcal disease as a result of underlying medical conditions. (cdc.gov)
  • MM is considered relative paucity of CNS invasion by MM an incurable disease despite various meth- in comparison with other tumours, whether ods of treatment, including autologous bone solid or haematological, remain unknown, marrow transplantation [ 3 ]. (who.int)
  • The U.S. Food and Drug Administration (FDA) is investigating the risk of severe hypocalcemia with serious outcomes, including hospitalization and death, in patients with advanced kidney disease on dialysis treated with the osteoporosis medicine Prolia (denosumab). (medlineplus.gov)
  • Our review of interim results from an ongoing safety study of Prolia suggests an increased risk of hypocalcemia, or low calcium levels in the blood, in patients with advanced kidney disease. (medlineplus.gov)
  • Because of the frequency and seriousness of these risks, we are alerting health care professionals and patients about them and that we are continuing to evaluate this potential safety issue with Prolia use in patients with advanced kidney disease, particularly those on dialysis. (medlineplus.gov)
  • Our review of the interim results from this ongoing safety study suggests an increased risk of hypocalcemia with Prolia in patients with advanced kidney disease. (medlineplus.gov)
  • HSCT) has significantly modified the prognosis of when the pathological process involves BM or when patients with hereditary or acquired hematological, hematopoietic toxicity is the limiting factor in the oncological and immunological diseases and it is the aggressive treatment of the disease. (bvsalud.org)
  • Investigators then will use these data to characterize the genetic subtypes of multiple myeloma based on the disease's responsiveness to specific treatments. (genomeweb.com)
  • According to the International Myeloma Foundation , an early relapse refers to the first, second, or third time the myeloma progresses after a period of remission. (healthline.com)
  • In addition, they noted that at the time of the analysis, 100 of the 140 patients treated with BCMA-directed CAR T at the two centers had relapsed. (medpagetoday.com)
  • While all prior approvals with CAR T have directed the engineered T-cells to CD19, a marker on the surface of malignancies derived from B-cells, this is the first approval of a B-cell maturation antigen (BCMA)-directed CAR T. Idecabtegene vicleucel or ide-cel (Abecma) is the first approval of a CAR T for multiple myeloma. (lls.org)
  • Ide-cel works by targeting a protein called BCMA that plays a key role in multiple myeloma. (lls.org)
  • The treatment is designed to bind to BCMA on myeloma cells and CD3 on T-cells, bringing them together and activating the T-cells to kill myeloma cells. (pharmtech.com)
  • Updated clinical data from the Phase 1/2 study sponsored by GSK plc (LSE/NYSE: GSK) evaluating nirogacestat in combination with low-dose belamaf (belantamab mafodotin-blmf), GSK's antibody-drug conjugate targeting BCMA, in patients with RRMM will be presented in a poster presentation. (advfn.com)
  • Our goal is to improve the outcomes for patients with multiple myeloma and we believe that developing a robust clinical data set across BCMA modalities and treatment lines can help us demonstrate where within the multiple myeloma treatment landscape nirogacestat has the greatest opportunity to maximize clinical benefit. (advfn.com)
  • A pathologists' task in assessing a prostate biopsy for cancerous tissue is of prime importance since failure to correctly identify tissue can lead to a failure to accurately diagnose the patient and predict their likely prognosis. (hrb.ie)
  • Multiple myeloma is most common among older patients who also face the worst prognosis and often have limited treatment option. (lls.org)
  • Multiple Myeloma on CureTalks in 2017: CAR T Cell Immunotherapy, Stem Cell Transplants, MRD Testing, MMRF Precision Medicine Model and More. (trialx.com)
  • They were raising funds for Multiple Myeloma Research Foundation (MMRF), which is a leading organisation working to find myeloma cure. (trialx.com)
  • The MMRF Precision Medicine Model - How Close to Multiple Myeloma Cure Are We? (trialx.com)
  • Raithel makes his point by participating in the Moving Mountains for Myeloma group climbs and hikes to raise funds for the Multiple Myeloma Research Foundation (MMRF). (karmanos.org)
  • All funds go directly to the MMRF for multiple myeloma research. (karmanos.org)
  • Download the MMRF Patient Toolkit-available in English and Spanish-or order a copy through the mail. (themmrf.org)
  • To deliver the highest possible level of patient care, the MMRF supports continuous learning for healthcare providers. (themmrf.org)
  • NEW YORK (GenomeWeb News) - The pharmaceutical firm Janssen R&D has teamed up with the Multiple Myeloma Research Foundation to help MMRF and its partners pursue their Personalized Medicine Initiative, part of which is a large clinical and molecular profiling study. (genomeweb.com)
  • MMRF said today that Janssen has joined its pre-competitive consortium, a group of partners that support the PMI and its Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile, or CoMMpass, program. (genomeweb.com)
  • Myeloma cells destroy bone , which releases calcium, a condition called hypercalcemia. (webmd.com)
  • Myeloma cells produce excess abnormal proteins, called paraproteins, in the bone marrow that can cause your blood to become so thick that it flows sluggishly in your body, a condition called hyperviscosity. (webmd.com)
  • 2005 Treatment of Jining serious radiation accidents and extremely severe bone marrow and intestinal radiation 2006 Developed an original creativity of microtransplantation for the treatment of leukemia. (wikipedia.org)
  • Multiple myeloma causes plasma cells to grow out of control, interfering with the bone marrow's ability to produce normal blood cells. (bannerhealth.com)
  • Multiple myeloma cells may also damage cells that keep bones strong, causing bone fractures and high calcium levels in the blood. (bannerhealth.com)
  • The signs and symptoms of multiple myeloma vary greatly but using the acronym C-R-A-B can help you remember its more common symptoms: C = Calcium (elevated), R = Renal failure, A = Anemia, B = Bone lesions. (bannerhealth.com)
  • After further discussing his treatment options, Raithel opted for a bone marrow transplant (BMT) in January 2016, performed by Lois Ayash, M.D. , hematologist and medical oncologist, and member of the Bone Marrow and Stem Cell Transplant Multidisciplinary Team . (karmanos.org)
  • In an interview with OncLive ® , Thomas G. Martin, MD, clinical professor of medicine in the Adult Leukemia and Bone Marrow Transplantation Program, associate director of the Myeloma Program, at the University of California, San Francisco, and coleader of the Cancer Immunology & Immunotherapy Program at the Helen Diller Family Comprehensive Cancer Center, spoke on the approval and potential future directions for the agent. (onclive.com)
  • In addition to these symptoms, some patients with MGRS may also experience bone pain, fractures, and an increased risk of infections. (articleinsider.com)
  • The current revolution in therapeutic advances in myeloma started with the introduction of thalidomide (Thalomid), guided by knowledge of the antiangiogenic properties of thalidomide and the recognition of relevance of bone marrow angiogenesis in myeloma. (cancernetwork.com)
  • Founded by Dr. James R. Berenson in 2003, IMBCR is a West Hollywood -based independent non‑profit cancer research institute dedicated to discovering and developing more effective treatments, and ultimately a cure for myeloma and bone cancer. (kron4.com)
  • Multiple myeloma is a cancer of plasma cells in which abnormal plasma cells multiply uncontrollably in the bone marrow and occasionally in other parts of the body. (msdmanuals.com)
  • In multiple myeloma, typically the majority of bone marrow elements are cancerous plasma cells. (msdmanuals.com)
  • Amyloidosis is often secondary to MM, but it may develop without MM. Patients with amyloidosis typically lack sufficient numbers of plasma cells in the bone marrow or sufficiently high levels of M protein to meet the diagnostic criteria for MM. (medscape.com)
  • Bone marrow aspirate demonstrating plasma cells of multiple myeloma. (medscape.com)
  • Malignant plasma cells in meningeal MM out of 2000 patients with bone marrow produce an immunoglobulin, MM, was reported was by Schluterman et al. (who.int)
  • Patients should not stop Prolia treatment without first consulting your health care professional, as stopping may worsen your bone condition. (medlineplus.gov)
  • BACKGROUND: Systemic lupus erythematosus (SLE) patients are often treated with glucocorticoids, which place them at risk of bone loss. (who.int)
  • Thanks to advances in treatment, over 50% of patients now survive 5 years compared to 35% in 2000. (lls.org)
  • Our scientific fraternity achieved a lot this year in the field of cancer treatment, giving new ray of hope to cancer patients with advances in immunotherapy, stem cell transplants and genomic testing. (trialx.com)
  • We talked to Dr. Saad Usmani of Levine Cancer Institute / Carolinas Healthcare System about the latest advances in immunotherapy for multiple myeloma. (trialx.com)
  • Hear Dr. Saad Usmani discuss new advances in immunotherapy in myeloma treatment HERE! (trialx.com)
  • Advances in multiple myeloma treatment are currently underway. (bannerhealth.com)
  • 5] Most importantly, therapeutic advances in myeloma have kept pace with developments in other areas and have led to risk-adapted treatment strategies for myeloma, thereby improving outcome for patients with myeloma. (cancernetwork.com)
  • Research shows survival rates have been increasing over recent years due to advances in treatment. (healthline.com)
  • Recent years have seen the emergence of immunotherapy as a leading form of treatment for multiple myeloma. (trialx.com)
  • Our initial investment in CAR T in the 1990's, when CAR T, and indeed immunotherapy to treat cancer was in its infancy, has turned into a game-changing therapeutic giving new hope to patients with limited treatment options and often very poor prognoses. (lls.org)
  • The use of a patient's immune system to fight cancer-cancer immunotherapy-is an exciting area of multiple myeloma research. (themmrf.org)
  • The immunotherapy module will review the mechanism of action, toxicities, dose adjustments, and important monitoring parameters of immunotherapy agents in the treatment of cancer patients. (hoparx.org)
  • Finally, essential information will be covered so the participant can effectively counsel patients on immunotherapy agents. (hoparx.org)
  • Immunotherapy is a type of cancer treatment that uses the body's immune system to find and attack cancer cells. (massgeneral.org)
  • Ryan J. Sullivan, MD, discusses treatment approaches with immunotherapy for patients with melanoma. (massgeneral.org)
  • Secondary endpoints were toxicities and previous treatment patterns, including refractory to lenalidomide, and their impact on final outcomes. (muni.cz)
  • [ 7 ] The oral proteasome inhibitor ixazomib showed improved PFS compared with placebo and may be an alternative choice for patients who do not tolerate lenalidomide. (medscape.com)
  • Select "Patients / Caregivers / Public" or "Researchers / Professionals" to filter your results. (aacr.org)
  • In a recent preclinical study published in Blood Cancer Discovery , the newest journal of the AACR, researchers investigated genetic abnormalities that could promote the development of multiple myeloma. (aacr.org)
  • In a prospective, longitudinal study, researchers investigated the potential for quality of life, fatigue, and physical functioning to return to previous levels in patients with AML after treatment. (oncologynurseadvisor.com)
  • Researchers report on a study investigating effects of ADT on prostate cancer health-related quality of life, sexual function, sexual bother, and mood for patients with prostate cancer and their partners. (oncologynurseadvisor.com)
  • Researchers identified socioeconomic and demographic factors related to oral treatment adherence in patients with multiple myeloma. (cancertherapyadvisor.com)
  • Yet immense amounts of data are generated daily by researchers as well as clinicians and patients themselves. (europa.eu)
  • The sheer volume of data involved will make it easier for researchers to uncover new insights into diseases and treatments, and accelerate the development of innovative, more effective medicines. (europa.eu)
  • HealthTree Podcast for Multiple Myeloma brings you patient-led interviews of the world's top multiple myeloma researchers. (player.fm)
  • Zeroing in on this kinase was encouraging, Goga said, because other researchers have shown that genetic-knockout mice that lack the entire family of PIM kinases are slightly smaller than normal mice, but "basically fine," indicating that a drug targeting just PIM1 may have manageable levels of toxicity in breast cancer patients. (ucsf.edu)
  • The abstract (P-136) was presented as a poster at the 20th International Myeloma Society (IMS) Annual Meeting in Athens, Greece. (biospace.com)
  • ABSTRACT Multiple myeloma (MM) is a systemic malignancy of pathologic plasma cells that is treat able with chemotherapeutic agents and irradiation, but rarely curable. (who.int)
  • Multiple myeloma (MM) remains an incurable plasma cell (PC) malignancy. (confex.com)
  • These results provide patients, caregivers, and healthcare professionals with a much more optimistic outlook for those dealing with this B-cell malignancy. (kron4.com)
  • Multiple myeloma (MM) is a debilitating malignancy that is part of a spectrum of diseases ranging from monoclonal gammopathy of unknown significance ( MGUS ) to plasma cell leukemia. (medscape.com)
  • Gracell has also launched an IIT evaluating GC012F for the treatment of refractory systemic lupus erythematosus (rSLE). (biospace.com)
  • From 2015 to 2017, the MAIA trial enrolled 737 patients with newly diagnosed multiple myeloma (median age = 73 years) ineligible for high-dose chemotherapy and stem cell transplant. (ascopost.com)
  • Chemotherapy and radiotherapy are associated with side effects which reduce tolerance to treatment and likelihood of tumour response. (cambridge.org)
  • The G8 and CARG chemotherapy toxicity assessment tools were found to predict early hospitalization/ER visits and death in older patients with cancer. (cancertherapyadvisor.com)
  • There was no significant difference in survival outcomes with trabectedin or physician's choice of chemotherapy. (cancertherapyadvisor.com)
  • The only treatment we have to offer these patients is chemotherapy, and we desperately need new options. (ucsf.edu)
  • About 25% of people with multiple myeloma report serious mental distress and depressive symptoms. (webmd.com)
  • If you have symptoms of AMS, it might be a side effect of your treatment. (webmd.com)
  • Patients were required to complete blood tests and a questionnaire about their symptoms and concerns before each consultation. (nih.gov)
  • If you experience symptoms of multiple myeloma, we can help. (bannerhealth.com)
  • What Are the Signs, Symptoms and Types of Multiple Myeloma? (bannerhealth.com)
  • Therefore, it is important for patients with MGRS to receive regular monitoring and treatment to prevent complications and manage symptoms. (articleinsider.com)
  • After you finish your first course of treatment, your cancer symptoms may subside. (healthline.com)
  • Advise patients on dialysis to immediately seek help if they experience symptoms of hypocalcemia. (medlineplus.gov)
  • The 20 patients who underwent either autologous or allogeneic stem cell transplant after progression had an OS of 23.2 months (95% CI 17.6 to NE). (medpagetoday.com)
  • The genetic factors underlying progression from MGUS to multiple myeloma remain unclear. (aacr.org)
  • The purpose of our study was to model genetic risk factors that may contribute to initiation and progression of multiple myeloma," said Marta Chesi, PhD , associate professor of medicine at the Mayo Clinic and lead author on the study. (aacr.org)
  • Primary endpoints included response rates based on International Myeloma Working Group criteria and survival measures, including progression-free survival (PFS) and overall survival (OS). (muni.cz)
  • These data provide a new progression-free survival benchmark in patients with newly diagnosed multiple myeloma who are transplant-ineligible," Dr. Facon said. (ascopost.com)
  • Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3. (medscape.com)
  • We were among the first centers in the world to use this drug and the first to have a patient who responded to it, back in 2006," says Dr. Stewart. (sciencedaily.com)
  • While myeloma care centers consider stem cell transplant as the standard first treatment, none of the patients in this clinical setting received a stem cell transplant. (kron4.com)
  • Our study was a multicenter observational analysis of patients treated with standard-of-care idecabtagene vicleucel at 11 medical centers in the United States. (cancernetwork.com)
  • In this study, we designed, implemented and evaluated a multidisciplinary team (MDT) myeloma clinic that provided participants with tailored exercise and lifestyle advice. (nih.gov)
  • Patients with monoclonal gammopathy of unknown significance, smoldering MM, plasma cell leukemia and amyloidosis were excluded. (scielo.br)
  • 6 , 9 The demonstrated efficacy, lack of myelosuppression, and overall tolerability of thalidomide provide a strong rationale for its incorporation in standard induction regimens for patients presenting with NDMM who may be eligible for ASCT. (haematologica.org)
  • Along with cost considerations, we focus on patient-specific factors, efficacy between products, and the data. (pharmacytimes.com)
  • Early CAR Ts demonstrating efficacy and safety and prior lines of treatment impact survival from CAR T in myeloma. (medscape.com)
  • The main efficacy outcome measures were overall response rate (ORR) and duration of response (DOR). (ahdbonline.com)
  • For the pharmaceutical industry, BD4BO will supply greater knowledge of how patients experience their condition, and which outcomes really matter, allowing them to better target potential treatments and demonstrate efficacy in real-life conditions. (europa.eu)
  • Notably, the fact that 77% of our patients would have been ineligible did not appear to impact efficacy. (cancernetwork.com)
  • In this position, she played a key role in the multidisciplinary care of and coordination for patients with immunoglobulin light chain (AL) amyloidosis and related diseases. (yale.edu)
  • Dr. Browning is a physician in the Smilow Multiple Myeloma and Gammopathies Programs and also sees patients in the Classical Hematology Clinic and she is incredibly passionate about the comprehensive management of patients with rare hematologic disorders including AL amyloidosis and hereditary hemorrhagic telangiectasia or HHT. (yale.edu)
  • Dr. Browning's clinical and research interests include evaluating new treatments for multiple myeloma, AL amyloidosis, and other hematologic diseases and their impact on outcomes and quality of life for patients. (yale.edu)
  • Dr. Browning has a clinical and research interest in the management of issues such as bleeding and clotting in individuals with multiple myeloma and AL amyloidosis. (yale.edu)
  • She is a member of the American Society of Hematology (ASH), the International Myeloma Society (IMS), and the International Society of Amyloidosis (ISA). (yale.edu)
  • The first six patients in each group will receive PS-341 alone for the first cycle, and thalidomide will be added on day 22. (knowcancer.com)
  • Initially, these patients will receive PS-341 alone and thalidomide will be added subsequently, if deemed safe based on the first 6 patients in each thalidomide dose cohort. (knowcancer.com)
  • In the same 2016 study, the median overall survival in patients who received a stem cell transplant and relapsed within 12 months was 23.1 months, compared to 122.2 months in those who relapsed after 12 months. (healthline.com)
  • Survival outcomes and quality of life for patients are improving all the time. (janssen.com)
  • In patients who achieved ?PR, the median PFS and OS were significantly longer compared to non-responders (median PFS (12.1 vs. 4.5 months, p?0.001 respectively), median OS (22.1 vs. 7.7 months, p?0.001, respectively). (muni.cz)
  • Total cost of care for multiple myeloma can be significantly affected by selection of dosing regimen. (pharmacytimes.com)
  • It is undeniable that medical anti-cancer options significantly improved over the past 10-15 years, yet it is also self-evident that they did not translate into improved outcome for advanced cancer patients in the real world, at least as far as survival rate is considered. (cambridge.org)
  • In the treatment of multiple myeloma, the addition of carfilzomib to a currently accepted two-drug combination produced significantly better results than using the two drugs alone, according to a worldwide research team. (sciencedaily.com)
  • A retrospective, descriptive analysis of all consecutive active NDMM patients recorded in the Uruguayan MM Registry between January 2011 and December 2018 were included. (scielo.br)
  • Study presented at 2018 ASCO Annual Meeting determined the feasibility of using a mindfulness intervention to improve quality of life and confidence in advance care planning discussions among patient-family caregiver dyads. (oncologynurseadvisor.com)
  • The main aim of this project is to develop a symptom management self care tool for patient with relapsed MM. MM is incurable and as a result of all novel treatments available patients live longer but not always with a exceptional QOL due to symptom burden. (hrb.ie)
  • Patients with high-risk NDMM, including those who are transplant-eligible, typically face suboptimal outcomes with the current standard of care. (biospace.com)
  • Doctors do not typically check people for myeloma during regular visits because currently there are no national screening recommendations. (ascopost.com)
  • Treatment for MGRS typically involves addressing the underlying cause of the condition, such as treating an underlying infection or removing a tumor that is producing the abnormal proteins. (articleinsider.com)
  • Treatment patterns and outcomes in real-world transplant-ineligible patients newly diagnosed with multiple myeloma. (bvsalud.org)
  • [ 13 ] are the most active regimens for transplant-ineligible patients, although addition of the anti-CD38 monoclonal antibody daratumumab to these regimens to drive deeper response is likely to become the new standard of care. (medscape.com)
  • Also, myeloma complications like kidney damage, frequent infections, high blood calcium, and more may change how well your brain works. (webmd.com)
  • Patients with MM often have neurologi- respectively) [ 8 ], which suggests that it cal complications, either due to metabolic can occur after a long period. (who.int)
  • Central to MMRF's mission is providing educational content no matter where patients and caregivers may be in the multiple myeloma diagnostic and treatment journey. (themmrf.org)
  • Our goal is to share resources and insights on clinical progress and precise treatments for all patients and their caregivers. (themmrf.org)
  • Dr. Paul Richardson of the Dana Farber Cancer Institute shares a mid-year myeloma review of ASCO, EHA and upcoming International Myeloma Society findings of the fast-moving research being performed in myeloma. (player.fm)
  • In results from the phase 1 trial, isatuximab plus carfilzomib showed an ORR of approximately 50% in carfilzomib-refractory patients. (onclive.com)
  • Carfilzomib is a proteasome inhibitor approved for use in 2012 by the U.S. Food and Drug Administration (FDA) for patients with advanced, end-stage multiple myeloma. (sciencedaily.com)
  • The combined effects of racial disparities in MM treatment with insurance type and access to Medicaid expansion on overall survival (OS), particularly in the real world, have not been investigated. (lls.org)
  • The study authors concluded, "After almost 5 years of follow-up, a significant and clinically meaningful overall survival improvement was demonstrated with the use of D-Rd vs Rd in patients with newly diagnosed multiple myeloma who are transplant-ineligible, representing a 32% reduction in the risk of death. (ascopost.com)
  • ICI-Induced Arthralgia Improves Survival in Cancer Patients To what extent is ICI-induced arthralgia associated with overall survival in cancer patients? (medscape.com)
  • Multiple myeloma is the most common blood cancer in African Americans. (lls.org)
  • Multiple myeloma (MM) is the most common blood cancer in Black individuals, who account for 20% of MM cases. (lls.org)
  • LLS funds lifesaving blood cancer research around the world, provides free information and support services, and is the voice for all blood cancer patients seeking access to quality, affordable, coordinated care. (lls.org)
  • Multiple myeloma is a cancer of antibody-producing cells-called plasma cells-that accounts for approximately 1.8 percent of new cancer cases in the United States. (aacr.org)
  • however, almost all patients are diagnosed after the cancer has progressed to a more advanced stage. (aacr.org)
  • Application of state of the art raman chemical imaging and chemometrics to accelerate and improve patient prostate biopsy assessment for cancer. (hrb.ie)
  • The KYPROLIS clinical program continues to focus on providing solutions for physicians and patients in treating this frequently relapsing and difficult-to-treat cancer. (amgen.com)
  • the duration of the effect is still being evaluated as some patients have been cancer-free for nearly a decade. (lls.org)
  • Multiple myeloma is a cancer derived from a specialized type of white blood cell called a plasma cells. (lls.org)
  • Myeloma is the second most common blood cancer in the U.S. and the most prevalent among African Americans. (lls.org)
  • Your gift will help support our mission to end cancer and make a difference in the lives of our patients. (mdanderson.org)
  • About 20% of cancer patients get hypercalcemia during their illness. (webmd.com)
  • Multiple myeloma (MM) is a type of malignant plasma cell and has a high incidence in malignant tumors of the blood system, accounting for ~2% of the total mortality of cancer ( 1 ). (spandidos-publications.com)
  • Multiple myeloma is a relatively uncommon cancer and its cause is unclear. (bannerhealth.com)
  • At Banner MD Anderson Cancer Center, we're advancing treatments for multiple myeloma, and helping patients live healthier, fuller lives. (bannerhealth.com)
  • Multiple myeloma is a cancer of plasma cells. (bannerhealth.com)
  • How Is Multiple Myeloma Cancer Treated? (bannerhealth.com)
  • According to the American Cancer Society, about 35,000 multiple myeloma cases are diagnosed yearly in the United States. (karmanos.org)
  • My perspective on Dr Dakhal and colleague's data is that myeloma treatment should be revisited in the light of this," commented invited discussant Asher Chanan-Khan, MD, from the Mayo Clinic Cancer Center in Jacksonville, Florida. (medscape.com)
  • Metastatic cancer patients should receive a quantitatively and qualitatively adequate diet, and in case of reduced tolerance of food, artificial nutrition is indicated. (cambridge.org)
  • Many reasons could explain the challenges still posed by advanced cancer in achieving clinically meaningful outcomes, among which patient-reported outcomes are gaining more relevance. (cambridge.org)
  • These findings highlight increasing success in treating myeloma, the second most common blood cancer, says Dr. Stewart. (sciencedaily.com)
  • Safety of Extended Interval Dosing ICIs A new study examines the safety of extended-interval dosing strategies in cancer patients receiving immune checkpoint inhibitors. (medscape.com)
  • Risks of Second Non-Breast Primaries Following Breast Cancer A better understanding of the potential risks of developing second primary malignancies among survivors of breast cancer could lead to better prevention and management strategies for these patients. (medscape.com)
  • Immune Checkpoint Inhibitor-induced Cutaneous Toxicities This study aimed to identify the clinical characteristics and overall incidence of cutaneous immune-related adverse events among cancer patients receiving immune checkpoint inhibitors. (medscape.com)
  • The expansion of Medicaid eligibility was associated with a nearly 3-fold increase in the proportion of Medicaid-covered patients enrolled in cancer treatment trials. (cancertherapyadvisor.com)
  • Among patients with ER+/HER2+ breast cancer, the median survival after distant recurrence increased from 2.3 years in 2000 to 4.8 years in 2019. (cancertherapyadvisor.com)
  • Gender balance in cancer surveys of patients with myeloproliferative neoplasms was found to have relatively little effect on survey outcomes. (cancertherapyadvisor.com)
  • Multiple myeloma is a type of blood cancer that forms in plasma cells. (healthline.com)
  • According to the National Cancer Institute (NCI)'s SEER database, the overall 5-year survival rate for multiple myeloma is 59.8% . (healthline.com)
  • Refractory means your cancer is no longer responding to treatment. (healthline.com)
  • IMBCR's innovative research provides cancer patients with greater longevity and an improved quality of life. (kron4.com)
  • Berenson Cancer Center is a comprehensive clinic that has specialized in the treatment of patients with multiple myeloma and related diseases for more than 20 years. (kron4.com)
  • Billy Costa of Kiss 108 Radio sits down with Dr. Kerry Reynolds and Dr. Chloe Villani to learn about the incredible team dynamic between research and clinical practice for patients at the Mass General Cancer Center. (massgeneral.org)
  • The health inequality impact of liquid biopsy to inform first-line treatment of advanced non-small cell lung cancer - a distributional cost-effectiveness analysis. (cdc.gov)
  • Outcomes in Premenopausal Patients with HR+/HER2- Breast Cancer and Lymph Node Micrometastasis Based on the 21-Gene Recurrence Score. (cdc.gov)
  • Racial and ethnic differences in perceptions of germline or somatic DNA sequencing among patients with advanced prostate, urothelial, or kidney cancer. (cdc.gov)
  • Integrating pharmacogenomic testing into paired germline and somatic genomic testing in patients with cancer. (cdc.gov)
  • Biomarker Testing, Treatment, and Outcomes in Patients With Advanced/Metastatic Non-Small Cell Lung Cancer Using a Real-World Database. (cdc.gov)
  • RÉSUMÉ Le myélome multiple est un cancer systémique caractérisé par des cellules plasmatiques anormales, qui peut être traité par des agents chimiothérapeutiques et par irradiation, mais qui est rarement curable. (who.int)
  • Multiple myeloma (MM) is a cancer of the The largest series, 23 patients with lepto- plasma cells. (who.int)
  • They had received a median of five previous treatment lines (including autologous stem cell transplant in 94.9% of patients), and most (83.5%) were triple class-refractory (refractory to ≥1 immunomodulatory drug, ≥1 proteasome inhibitor, and ≥1 anti-CD38 monoclonal antibody). (medpagetoday.com)
  • We look at, for example, patients with poor renal function and how the data look and reflect that. (pharmacytimes.com)